Tech shares are getting hit hard after the worst US chip sell off since 2020, and plenty of fast growers suddenly look a lot riskier. Reliable cash payouts feel very different when screens are full of red. That is where companies that steadily lift both earnings and dividends can matter. This article walks through three stocks from a 2% to 5% dividend growth universe that fit that profile.
The three stocks in this piece are only a starter pack, and the full screen surfaced 41 more companies with similar income and earnings stories that are not covered below. To see the full list and quickly identify your own higher conviction ideas, head straight into the Growing Dividend Payers with 2-5% yield screener
McDonald's (MCD)
McDonald's is a classic fit for this growing dividend payer theme because its franchise-heavy structure generates recurring fees and rent that can help support rising payouts even when restaurant traffic or menu trends hit a soft patch.
McDonald's runs and franchises its fast food restaurants globally under the McDonald's brand, using royalty and rental income from franchisees to underpin steady cash generation. The stock carries a market value of about US$198.3b.
"However, the weakness of the economy and consumer spending will put pressure in revenue growth during the next couple of years, coupling with the fact that a more health aware customer (resulting, or not, from new obesity drugs) will probably opt for other choices."
How well that recurring fee engine holds up against one quiet but crucial pressure could shape both margins and the runway for future dividend increases.
That quiet pressure is exactly what the full narrative for McDonald's unpacks, separating short term consumer headwinds from the factors that could keep McDonald's cash engine compounding over time.
Amgen (AMGN)
Amgen focuses on biologic and specialty drugs that patients stay on for years, which can create the kind of recurring cash flow this 2% to 5% dividend theme looks for, especially when those therapies span arthritis, osteoporosis, cardiovascular disease, cancer and more.
Amgen generates about US$38.9b from its Human Therapeutics segment, reflecting a portfolio of long-duration biologic treatments, and the stock has a market value near US$249b.
"Dividend covered about 2x by free cash flow; debt from the Horizon deal is being paid down."
The real tension for Amgen’s dividend story lies in how far management can keep funding new drug launches without quietly squeezing future margin headroom.
That trade off between funding fresh science and protecting future cash can be seen more clearly inside the full narrative for Amgen, where Amgen’s pipeline, pricing power and balance sheet all get pulled apart to show what could accelerate or stall the story from here.
Lockheed Martin (LMT)
Lockheed Martin fits this growing dividend payer theme through long contract cycles in defense and space, where multi year programs turn into recurring cash that can help support rising payouts even as budgets, politics and input costs keep shifting in the background.
"Lockheed Martin is moving munitions like PAC‑3, THAAD, PrSM and JATM onto seven year framework agreements that aim to triple or quadruple production and allow the company to retain a larger share of cost savings from capacity investments such as robotics in Camden. This can support higher future revenue and structurally stronger net margins."
The real test is how long that production ramp and cost discipline can hold before one pressure point quietly changes the margin story.
Lockheed Martin is a US$137.5b aerospace and defense group whose Aeronautics arm generates about US$32.2b in sales, with Missiles and Fire Control at US$17.3b, Rotary and Mission Systems at US$20.0b and Space at roughly US$13.9b, all feeding largely government and allied defense customers.
If you want to see how that pressure point could reshape the story, the full narrative for Lockheed Martin lays out where Lockheed Martin’s cash engine might be accelerating or stalling.
Seeking Fresh Alternatives Before They Fly
Markets can change quickly. New themes may gain attention while older ideas lose focus. Review fresh stock sets that are under the radar for now and consider them before they become widely followed.
- Identify resilient potential compounders early by reviewing the 32 resilient stocks with low risk scores before it attracts broader interest among lower volatility ideas.
- Monitor where cash generation aligns with AI-related activity by focusing on the 41 profitable AI stocks that aren't just burning cash while valuations still reflect earlier expectations.
- Follow the development of future energy systems by exploring the 16 nuclear energy infrastructure stocks while these infrastructure-related stories remain less prominent.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com